Properties (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
thiazole derivatives
thiazole ring piperazine derivatives C20H25N3O2S antipsychotic agents phenyl group piperazine ring |
| gptkbp:clinicalTrials |
gptkb:Asia
gptkb:USA Europe Phase II |
| gptkbp:collaborations |
gptkb:ABC_Pharma
|
| gptkbp:compatibleWith |
high
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:contraindication |
anxiety
nausea constipation |
| gptkbp:enrollment |
adults
schizophrenia_patients |
| https://www.w3.org/2000/01/rdf-schema#label |
WLR-679
|
| gptkbp:impact |
drowsiness
dry mouth weight gain |
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not available
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operational_status |
clinical trials
|
| gptkbp:origin |
N-(4-(4-(dimethylamino)phenyl)-1,3-thiazol-2-yl)-2-(4-methylpiperazin-1-yl)phenyl)acetamide
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
gptkb:Neuropharmacology_Journal
Journal of Medicinal Chemistry Clinical Psychopharmacology Pharmaceutical_Research |
| gptkbp:related_to |
WLR-678
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research |
promising results
favorable safety profile improved symptoms potential for further development |
| gptkbp:research_areas |
neuropharmacology
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
under investigation
|
| gptkbp:targets |
Dopamine receptor
|
| gptkbp:triggerType |
Dopamine D2 receptor antagonist
|
| gptkbp:uses |
antipsychotic medication
|
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
375.56 g/mol
|